|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
EP0590058B1
(en)
|
1991-06-14 |
2003-11-26 |
Genentech, Inc. |
HUMANIZED Heregulin ANTIBODy
|
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
|
US7087411B2
(en)
|
1999-06-08 |
2006-08-08 |
Regeneron Pharmaceuticals, Inc. |
Fusion protein capable of binding VEGF
|
|
US20070258987A1
(en)
|
2000-11-28 |
2007-11-08 |
Seattle Genetics, Inc. |
Recombinant Anti-Cd30 Antibodies and Uses Thereof
|
|
US7332585B2
(en)
|
2002-04-05 |
2008-02-19 |
The Regents Of The California University |
Bispecific single chain Fv antibody molecules and methods of use thereof
|
|
SI1680140T1
(sl)
|
2003-10-16 |
2011-08-31 |
Imclone Llc |
Inhibitorji receptorja-1 za fibroblastni rastni faktor in metode za zdravljenje z le-temi
|
|
CA2556752C
(en)
|
2004-02-23 |
2016-02-02 |
Genentech, Inc. |
Heterocyclic self-immolative linkers and conjugates
|
|
TW200539855A
(en)
|
2004-03-15 |
2005-12-16 |
Wyeth Corp |
Calicheamicin conjugates
|
|
AR056857A1
(es)
|
2005-12-30 |
2007-10-24 |
U3 Pharma Ag |
Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
|
|
US7750116B1
(en)
|
2006-02-18 |
2010-07-06 |
Seattle Genetics, Inc. |
Antibody drug conjugate metabolites
|
|
DE502006007538D1
(de)
|
2006-08-31 |
2010-09-09 |
Treofan Germany Gmbh & Co Kg |
Biaxial orientierte Elektroisolierfolie
|
|
US8236074B1
(en)
|
2006-10-10 |
2012-08-07 |
Us Synthetic Corporation |
Superabrasive elements, methods of manufacturing, and drill bits including same
|
|
EP2094733A1
(en)
|
2006-11-03 |
2009-09-02 |
U3 Pharma GmbH |
Fgfr4 antibodies
|
|
AU2007353412A1
(en)
|
2006-11-21 |
2008-11-20 |
Fox Chase Cancer Center |
Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof
|
|
RU2448979C2
(ru)
|
2006-12-14 |
2012-04-27 |
Ридженерон Фармасьютикалз, Инк. |
Антитела человека к дельта-подобному лиганду-4 человека
|
|
NZ579644A
(en)
|
2007-02-16 |
2012-05-25 |
Merrimack Pharmaceuticals Inc |
Antibodies against erbb3 and uses thereof
|
|
WO2008122039A2
(en)
|
2007-04-02 |
2008-10-09 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Selenocysteine mediated hybrid antibody molecules
|
|
US7985557B2
(en)
|
2007-05-23 |
2011-07-26 |
Ventana Medical Systems, Inc. |
Polymeric carriers for immunohistochemistry and in situ hybridization
|
|
US8815906B2
(en)
|
2008-03-19 |
2014-08-26 |
Chembridge Corporation |
Tyrosine kinase inhibitors
|
|
UA108598C2
(xx)
|
2008-04-30 |
2015-05-25 |
|
Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери)
|
|
FR2933702A1
(fr)
|
2008-07-08 |
2010-01-15 |
Sanofi Aventis |
Antagonistes specifiques du recepteur fgf-r4
|
|
ES2560807T3
(es)
|
2008-07-21 |
2016-02-22 |
Polytherics Limited |
Nuevos reactivos y procedimiento de conjugación de moléculas biológicas
|
|
AR073770A1
(es)
|
2008-10-20 |
2010-12-01 |
Imclone Llc |
Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden
|
|
KR20150036824A
(ko)
|
2009-03-20 |
2015-04-07 |
제넨테크, 인크. |
이중특이적 항-ｈｅｒ 항체
|
|
ES2549769T3
(es)
|
2009-03-25 |
2015-11-02 |
Genentech, Inc. |
Anticuerpos anti-FGFR3 y métodos que emplean los mismos
|
|
JP2012525432A
(ja)
|
2009-04-29 |
2012-10-22 |
トレリス バイオサイエンス リミテッド ライアビリティー カンパニー |
ヘレグリン共役型ｈｅｒ３と免疫反応性の改善された抗体
|
|
US8487083B2
(en)
|
2009-06-30 |
2013-07-16 |
OOO “Oncomax” |
Monoclonal antibodies capable of simultaneously binding domains II and IIIc of type 1 fibroblast growth factor receptor
|
|
JO3182B1
(ar)
|
2009-07-29 |
2018-03-08 |
Regeneron Pharma |
مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
|
|
DK2889624T3
(en)
|
2009-08-10 |
2018-12-10 |
Ucl Business Plc |
Reversible covalent bonding of functional molecules
|
|
JP2013507926A
(ja)
|
2009-10-14 |
2013-03-07 |
メリマック ファーマシューティカルズ インコーポレーティッド |
ＩＧＦ−１Ｒ及びＥｒｂＢ３シグナル伝達を標的とする二重特異的結合剤及びその使用
|
|
PH12012501157A1
(en)
|
2009-12-22 |
2012-10-29 |
Roche Glycart Ag |
Anti-her3 antibodies and uses thereof
|
|
US8895001B2
(en)
|
2010-03-11 |
2014-11-25 |
Merrimack Pharmaceuticals, Inc. |
Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers
|
|
KR101764453B1
(ko)
|
2010-04-09 |
2017-08-02 |
아베오 파마슈티컬즈, 인크. |
항-erbb3 항체
|
|
PT2528625E
(pt)
|
2010-04-15 |
2013-10-17 |
Spirogen Sarl |
Pirrolobenzodiazepinas e conjugados das mesmas
|
|
US9932403B2
(en)
|
2010-05-20 |
2018-04-03 |
Ablynx Nv |
Biological materials related to HER3
|
|
US20130244905A1
(en)
|
2010-07-06 |
2013-09-19 |
Ed Grabczyk |
Reporter for RNA Polymerase II Termination
|
|
WO2012015674A1
(en)
|
2010-07-26 |
2012-02-02 |
Eli Lilly And Company |
THERAPEUTIC USES OF AN FGFR1c ANTIBODY
|
|
ME02637B
(me)
|
2010-08-20 |
2017-06-20 |
Novartis Ag |
Antitela za receptor 3 faktora rasta epiderma (her3)
|
|
TW201302793A
(zh)
|
2010-09-03 |
2013-01-16 |
Glaxo Group Ltd |
新穎之抗原結合蛋白
|
|
CA2813796C
(en)
|
2010-10-18 |
2019-01-15 |
Mediapharma S.R.L. |
Erbb3 binding antibody
|
|
US9155802B2
(en)
|
2010-11-01 |
2015-10-13 |
Symphogen A/S |
Pan-HER antibody composition
|
|
WO2012059857A2
(en)
|
2010-11-01 |
2012-05-10 |
Symphogen A/S |
Pan-her antibody composition
|
|
ITRM20100577A1
(it)
|
2010-11-02 |
2012-05-03 |
Takis Srl |
Immunoterapia contro il recettore erbb-3
|
|
RU2440142C1
(ru)
|
2011-02-07 |
2012-01-20 |
Общество С Ограниченной Ответственностью "Онкомакс" |
Антитело, останавливающее или замедляющее рост опухоли (варианты), способ подавления роста опухоли, способ диагностики злокачественных образований
|
|
CA2828890A1
(en)
|
2011-04-07 |
2012-10-11 |
Genentech, Inc. |
Anti-fgfr4 antibodies and methods of use
|
|
MX336197B
(es)
|
2011-04-19 |
2016-01-11 |
Merrimack Pharmaceuticals Inc |
Anicuerpos anti-igf-1r y anti-erbb3 monoespecificos y biespecificos.
|
|
WO2012158704A1
(en)
|
2011-05-16 |
2012-11-22 |
Genentech, Inc. |
Fgfr1 agonists and methods of use
|
|
US9127065B2
(en)
|
2011-05-19 |
2015-09-08 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Anti-human HER3 antibodies and uses thereof
|
|
DK2714685T3
(en)
|
2011-05-27 |
2017-01-09 |
Ambrx Inc |
FORMATIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID BOUND dolastatin
|
|
US8815226B2
(en)
|
2011-06-10 |
2014-08-26 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
|
WO2012176779A1
(ja)
|
2011-06-20 |
2012-12-27 |
協和発酵キリン株式会社 |
抗ｅｒｂＢ３抗体
|
|
CA2842860A1
(en)
|
2011-07-28 |
2013-01-31 |
Sea Lane Biotechnologies, Llc |
Sur-binding proteins
|
|
WO2013048883A2
(en)
*
|
2011-09-30 |
2013-04-04 |
Regeneron Pharmaceuticals, Inc. |
Anti-erbb3 antibodies and uses thereof
|
|
US9273143B2
(en)
|
2011-09-30 |
2016-03-01 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
|
|
EP2764364B1
(en)
|
2011-10-06 |
2021-08-18 |
Aveo Pharmaceuticals, Inc. |
Predicting tumor response to anti-erbb3 antibodies
|
|
AU2012322934B2
(en)
|
2011-10-14 |
2016-09-08 |
Medimmune Limited |
Pyrrolobenzodiazepines
|
|
JP6166728B2
(ja)
|
2011-10-14 |
2017-07-19 |
メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ |
ピロロベンゾジアゼピンの製造に有用な合成方法及び中間体
|
|
CA2850373C
(en)
|
2011-10-14 |
2019-07-16 |
Seattle Genetics, Inc. |
Pyrrolobenzodiazepines and targeted conjugates
|
|
CA2850375C
(en)
|
2011-10-14 |
2019-07-02 |
Seattle Genetics, Inc. |
Pyrrolobenzodiazepines and targeted conjugates
|
|
WO2013068874A1
(en)
|
2011-11-11 |
2013-05-16 |
Pfizer Inc. |
Antibody-drug conjugates
|
|
AR088941A1
(es)
|
2011-11-23 |
2014-07-16 |
Bayer Ip Gmbh |
Anticuerpos anti-fgfr2 y sus usos
|
|
CN108424456B
(zh)
|
2011-11-23 |
2022-04-26 |
医学免疫有限责任公司 |
特异于her3的结合分子及其用途
|
|
BR112014013526A8
(pt)
|
2011-12-05 |
2017-06-13 |
Igenica Biotherapeutics Inc |
conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados
|
|
CN108341873B
(zh)
|
2011-12-05 |
2022-03-25 |
诺华股份有限公司 |
表皮生长因子受体3(her3)的抗体
|
|
WO2013148315A1
(en)
|
2012-03-27 |
2013-10-03 |
Genentech, Inc. |
Diagnosis and treatments relating to her3 inhibitors
|
|
AU2013247645B2
(en)
|
2012-04-09 |
2019-02-14 |
Daiichi Sankyo Company, Limited |
Anti-FGFR2 antibody
|
|
TWI641619B
(zh)
|
2012-06-25 |
2018-11-21 |
美商再生元醫藥公司 |
抗－ｅｇｆｒ抗體及其用途
|
|
US9345766B2
(en)
|
2012-08-30 |
2016-05-24 |
Merrimack Pharmaceuticals, Inc. |
Combination therapies comprising anti-ERBB3 agents
|
|
HRP20180268T4
(hr)
|
2012-10-23 |
2026-03-27 |
Synaffix B.V. |
Modificirano antitijelo, konjugat antitijela i postupak za njihovu pripremu
|
|
JP2015534997A
(ja)
|
2012-10-25 |
2015-12-07 |
ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． |
ＥｒｂＢ３と結合する抗原結合タンパク質
|
|
WO2014105849A1
(en)
|
2012-12-28 |
2014-07-03 |
Xoma (Us) Llc |
Antibodies specific for fgfr4 and methods of use
|
|
AR094403A1
(es)
|
2013-01-11 |
2015-07-29 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos anti-her3
|
|
JP2016510751A
(ja)
*
|
2013-03-06 |
2016-04-11 |
ジェネンテック， インコーポレイテッド |
抗がん剤耐性を治療及び予防する方法
|
|
US10239951B2
(en)
|
2013-05-08 |
2019-03-26 |
Zymeworks Inc. |
Bispecific HER2 and HER3 antigen binding constructs
|
|
US11305012B2
(en)
|
2013-09-24 |
2022-04-19 |
Medimmune, Llc |
Binding molecules specific for HER3 and uses thereof
|
|
CA2924386C
(en)
|
2013-10-04 |
2021-07-20 |
F. Hoffmann-La Roche Ag |
Antibodies specifically binding to her3
|
|
WO2015066543A1
(en)
|
2013-11-01 |
2015-05-07 |
Board Of Regents, The University Of Texas System |
Targeting her2 and her3 with bispecific antibodies in cancerous cells
|
|
KR102127408B1
(ko)
|
2014-01-29 |
2020-06-29 |
삼성전자주식회사 |
항 Her3 scFv 단편 및 이를 포함하는 항 c-Met/항 Her3 이중 특이 항체
|
|
WO2015130554A2
(en)
|
2014-02-20 |
2015-09-03 |
Merrimack Pharmaceuticals, Inc. |
Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith
|
|
DK3805268T3
(da)
|
2014-02-28 |
2025-01-20 |
Merus Nv |
Antistof, der binder erbb-2 og erbb-3
|
|
CA2941030C
(en)
|
2014-02-28 |
2025-05-13 |
Merus N.V. |
ANTIBODIES THAT BIND TO EGFR AND ERBB3
|
|
US10745490B2
(en)
|
2014-04-11 |
2020-08-18 |
Celldex Therapeutics, Inc. |
Anti-ErbB antibodies and methods of use thereof
|
|
KR102223502B1
(ko)
|
2014-05-09 |
2021-03-05 |
삼성전자주식회사 |
항 c-Met/항 EGFR/항 Her3 다중 특이 항체 및 이의 이용
|
|
JP6695812B2
(ja)
|
2014-05-14 |
2020-05-20 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Ｈｅｒ３のベータヘアピン及びｈｅｒ２のドメインｉｉに結合するｈｅｒ３／ｈｅｒ２二重特異性抗体
|
|
WO2016055916A1
(en)
*
|
2014-10-06 |
2016-04-14 |
Novartis Ag |
Therapeutic combination for the treatment of cancer
|